Ten‐Year Follow‐Up After 96 Weeks Treatment With Peginterferon Plus Tenofovir in Hepatitis D (HIDIT‐II): Improved Clinical Outcome After Combination Therapy
United European Gastroenterology Journal · 2026-02 · 14 (1)
DOI: 10.1002/ueg2.70153 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift United European Gastroenterology Journal, online erschienen am 29.11.2025. Verfasst von Cihan Yurdaydin und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology & Hepatology, Koc University Medical School, Istanbul, Turkey. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis D, Chronic, Interferon-alpha, Polyethylene Glycols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: HepNet Study-House, F. Hoffmann-La Roche, Gilead Sciences.
Abstract (Originalsprache)
Background
Chronic delta hepatitis represents a major health burden. Until recently, pegylated interferon‐alfa‐2a (PEG‐IFNα) therapy was the only treatment option for patients infected with hepatitis D virus (HDV). The aim of this study was to evaluate 10‐year long‐term clinical and virological outcomes after 96 weeks of treatment with PEG‐IFNα with or without tenofovir disoproxil fumarate (TDF).
Methods
We conducted a retrospective follow‐up study of the Hep‐Net‐International‐Delta‐Hepatitis‐Intervention‐Study 2 (HIDIT‐II trial). Patients had received 96 weeks of treatment with either PEG‐IFNα‐2a plus TDF or PEG‐IFNα‐2a alone. Patients were included if they had completed the 96‐week treatment period and had at least one follow‐up visit (PEG‐IFNα‐2a + TDF; n = 51, PEG‐IFNα‐2a alone; n = 56).
Results
Patients who received PEG‐IFNα‐2a + TDF were younger (37 vs. 42 years) and no significant differences were observed in other baseline characteristics between the two treatment arms. A total of 26 patients (24%) developed one or more liver‐related endpoints after a mean time of 8.4 years. The incidence of endpoints was significantly lower in the combination group (14% vs. 34%, p = 0.02). The development of liver‐related endpoints was also associated with non‐response to therapy (HDV RNA and HBsAg), elevated HBV DNA at week 72, and baseline age, cirrhosis, platelets, INR, AST, GGT, bilirubin and albumin according to the Cox regression model.
Conclusions
The long‐term follow‐up of this large randomised clinical trial demonstrates that combination therapy with TDF and virological response to PEG‐IFNα‐2a (undetectable HDV RNA and HBsAg loss) were associated with better clinical outcomes. Trial Registration NCT00932971, EudraCT 2008‐005560‐13
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology & Hepatology, Koc University Medical School, Istanbul, Turkey.
- Department of Gastroenterology, Hepatology, Infectious Diseases und Endocrinology, Hannover Medical School, Hannover, Germany.
- HepNet Study-House/ German Liver Foundation, Hannover, Germany.
- D-SOLVE Consortium, an EU Horizon Europe Funded Project (No 101057917), Hannover, Germany.
- Institutul National de Boli Infectioase "Prof Dr Matei Bals", Bucharest, Romania.
- Dicle University Medical Faculty, Diyarbakir, Turkey.
ORCID-Profile: Cihan Yurdaydin, Julia Kahlhöfer, Ulus S Akarca, Hans H Bock, George V Papatheodoridis, Münevver Demir, Svenja Hardtke, Onur Keskin, Ramazan Idilman, Markus Cornberg, Heiner Wedemeyer, Anika Wranke
Förderung
- HepNet Study-House
- F. Hoffmann-La Roche
- Gilead Sciences
Zitieren
APA
Yurdaydin, C., Kahlhöfer, J., Caruntu, F. A., Yalcin, K., Gürel, S., Akarca, U. S., Sprinzl, K., Bock, H. H., Bockmann, J. H., Papatheodoridis, G. V., Merle, U., Demir, M., Hardtke, S., Keskin, O., Idilman, R., Cornberg, M., Wedemeyer, H., & Wranke, A. (2026). Ten‐Year Follow‐Up After 96 Weeks Treatment With Peginterferon Plus Tenofovir in Hepatitis D (HIDIT‐II): Improved Clinical Outcome After Combination Therapy. United European Gastroenterology Journal, 14(1). https://doi.org/10.1002/ueg2.70153
Vancouver
Yurdaydin C, Kahlhöfer J, Caruntu FA, Yalcin K, Gürel S, Akarca US, et al. Ten‐Year Follow‐Up After 96 Weeks Treatment With Peginterferon Plus Tenofovir in Hepatitis D (HIDIT‐II): Improved Clinical Outcome After Combination Therapy. United European Gastroenterology Journal. 2026;14(1). doi:10.1002/ueg2.70153
BibTeX
@article{Yurdaydin2026,
author = {Yurdaydin, Cihan and Kahlhöfer, Julia and Caruntu, Florin Alexandru and Yalcin, Kendal and Gürel, Selim and Akarca, Ulus S and Sprinzl, Kathrin and Bock, Hans H and Bockmann, Jan-Hendrik and Papatheodoridis, George V and Merle, Uta and Demir, Münevver and Hardtke, Svenja and Keskin, Onur and Idilman, Ramazan and Cornberg, Markus and Wedemeyer, Heiner and Wranke, Anika},
title = {Ten‐Year Follow‐Up After 96 Weeks Treatment With Peginterferon Plus Tenofovir in Hepatitis D (HIDIT‐II): Improved Clinical Outcome After Combination Therapy},
journal = {United European Gastroenterology Journal},
year = {2026},
volume = {14},
number = {1},
doi = {10.1002/ueg2.70153}
}
EUVIMED